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Graphical Abstract 17 
 18 
 19 
 20 
 21 
Highlights 22 
N-Cinnamoyl anthranilate derivatives (CADs) are TRPA1 modulators 23 
CADs with electron-withdrawing groups are TRPA1 agonists with desensitizing effects 24 
CADs with strongly electron-donating groups are TRPA1 antagonists 25 
CADs modulate TRPA1 through non-covalent interactions  26 
F944A mutants show reduced sensitivity towards CADs and many other TRPA1 modulators   27 
  28 
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Abstract 29 
The transient receptor potential ankyrin 1 (TRPA1) channel is a non-selective cation channel, 30 
which detects noxious stimuli leading to pain, itch and cough. However, the mechanism(s) of 31 
channel modulation by many of the known, non-reactive modulators has not been fully 32 
elucidated. N-cinnamoylanthranilic acid derivatives (CADs) contain structural elements from 33 
the TRPA1 modulators cinnamaldehyde and flufenamic acid, so it was hypothesized that 34 
specific modulators could be found amongst them and more could be learnt about modulation 35 
of TRPA1 with these compounds. A series of CADs was therefore screened for agonism and 36 
antagonism in HEK293 cells stably transfected with WT-human (h)TRPA1, or C621A, 37 
F909A or F944A mutant hTRPA1. Derivatives with electron-withdrawing and/or electron-38 
donating substituents were found to possess different activities. CADs with inductive 39 
electron-withdrawing groups were agonists with desensitizing effects, and CADs with 40 
electron-donating groups were either partial agonists or antagonists. Site-directed 41 
mutagenesis revealed the CADs do not undergo conjugate addition reaction with TRPA1 and 42 
reveal that F944 is a key residue involved in the non-covalent modulation of TRPA1 by 43 
CADs, as well as many other structurally distinct non-reactive TRPA1 ligands already 44 
reported. 45 
Keywords: transient receptor potential ankyrin 1; TRPA1; TRP; N-cinnamoylanthranilic 46 
acid; tranilast; calcium signaling; binding site; non-covalent 47 
 48 
Abbreviations Used 49 
[Ca2+]i, intracellular calcium ion; CAD, N-cinnamoylanthranilic acid derivative; hTRPA1, 50 
human transient receptor potential ankyrin 1; hTRPM8, human transient receptor potential 51 
melastatin 8.  52 
 53 
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1. Introduction 55 
The human transient receptor potential ankyrin 1 (hTRPA1) channel [1] is predominantly 56 
expressed in the primary afferent (sensory) neurons [2] including trigeminal [3], dorsal root 57 
[4] and nodose ganglia, [5] and acts as a detector of chemical, mechanical and thermal stimuli 58 
[6]. TRPA1 is known to be involved in pain, itch, [7, 8] inflammatory diseases like arthritis 59 
[9], chronic obstructive pulmonary disease (COPD), and other respiratory diseases including 60 
chronic cough and asthma [6, 10]. There are many compounds known to modulate TRPA1, 61 
among them compounds containing reactive electrophilic groups that activate the channel 62 
through covalent modification of cysteine or lysine residues at the N-terminus of the protein 63 
[11, 12]. However, TRPA1 is also modulated by compounds through non-covalent 64 
interactions only. Mutagenesis and chimeric approaches have been utilized to elucidate the 65 
interactions of individual non-reactive chemicals with the channel [12-17]. However, the 66 
non-covalent mechanism(s) of modulation (activation or blocking) by compounds with 67 
distinct structures are currently much less well determined, hindering our understanding of 68 
the role of TRPA1 in diseases, and development of drugs targeting the channel. 69 
Analogues of N-cinnamoylanthranilic acid (1) have shown a range of biological activities, 70 
including anti-allergic, anti-histaminic, anti-inflammatory, anti-asthmatic, [18, 19] anti-71 
oxidant, [20] anti-fibrotic [21], anti-proliferative, [22] anti-cancer, [23] anti-platelet, [24] 72 
anti-coagulant [25] and as modulators of B-cells and T-cells, [26, 27], and are under 73 
investigations for several medicinal applications. The derivative N-(3,4-74 
dimethoxycinnamoyl)anthranilic acid (11, Tranilast™ or Rizaben™) is an anti-inflammatory 75 
drug that has been used in South Korea and Japan for over twenty years to treat allergic 76 
diseases such as bronchial asthma, allergic rhinitis, hypertrophic scars and scleroderma [18, 77 
21, 28]. N-cinnamoylanthranilate derivatives (CADs) also contain structural elements from 78 
two classes of known TRPA1 modulators, namely the α,β-unsaturated carbonyl moiety found 79 
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in the agonist cinnamaldehyde (CA), [29] and the anthranilate moiety found in the agonist 80 
flufenamic acid (FFA) and related fenamates [30]. It was therefore anticipated that discovery 81 
of CAD agonists or antagonists of TRPA1 could be used to learn about the modulation of the 82 
channel by non-reactive compounds.  83 
CADs have previously been shown to inhibit other TRP channels. For example N-(p-84 
amylcinnamoyl)anthranilic acid (ACA), a PLA2 inhibitor, [31] was characterized as a novel 85 
TRPM2, TRPM8, TRPC3, TRPC6 and TRPV1 channel blocker [32]. Similarly, N-(3-86 
methoxyphenyl)-4-chlorocinnamide (SB366791) selectively blocks TRPV1 [33], yet is 87 
inactive against TRPM8 [34]. The anthranilates 5-nitro-2-(phenethylamino)benzoic acid 88 
(NPEB), 5-nitro-2-(phenethylamino)benzamide (NPBA) and 5-nitro-2-(3-89 
phenylpropylamino)benzoic acid (NPPB), the latter which bears some overall similarity to 90 
CAD 1), selectively activates TRPA1 [35]. Therefore, to investigate both the structure-91 
activity relationship (SAR) and pharmacology of CADs as TRPA1 modulators, we set out to 92 
synthesize and screen a series of compounds against TRPA1-transfected HEK293 cells.  93 
 94 
2. Materials and Methods 95 
2.1 Materials. 96 
2.1.1 Commercial TRPA1 modulators. Cinnamaldehyde (CA, ≥ 95 %, natural), acrolein 97 
(ACR, analytical standard), allyl isothiocyanate (AITC, analytical standard), menthol (99 %), 98 
(˗)-menthol and 5-nitro-2-(3-phenylpropylamino)benzoic (NPPB) were purchased from 99 
Sigma-Aldrich. Calcimycin (calcium ionophore, A23187), thymol (> 99.5 %), carvacrol (98 100 
%), eugenol (99 %), cyclohexylcarbamic acid 3ʹ-carbamoyl-biphenyl-3-yl ester (URB597, ≥ 101 
98 %), (-)-nicotine (≥ 99 %), N-(p-amylcinnamoyl)anthranilic acid (ACA, ≥ 98 %), 102 
probenecid, 4-(4-chlorophenyl)-3-methylbut-3-en-2-oxime (AP18) and 2-(1,3-dimethyl-2,6-103 
dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)-N-(4-isopropylphenyl)acetamide (HC030031) were 104 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
7 
 
purchased from Sigma-Aldrich. (1E,3E)-1-(4-fluorophenyl)-2-methylpent-1-en-3-one oxime 105 
(A967079), N-(3-aminopropyl)-2-((3-methylbenzyl)oxy)-N-(thiophen-2-ylmethyl)benzamide 106 
hydrochloride (AMTB.HCl) and SB366791 were purchased from Tocris Bioscience. Ethyl 107 
((1R,2S,5R)-2-isopropyl-5-methylcyclohexane-1-carbonyl)glycinate (WS5) was from 108 
Millennium Specialty Chemicals Inc., Procter & Gamble, flufenamic acid (analytical 109 
standard) was from Fluka Analytical, mefenamic acid (98 %) was from Johnson Matthey 110 
Company and diclofenac (> 98 %) was from Tokyo Chemical Industry. Nordihydroguaiaretic 111 
acid (NDGA) and farnesylthiosalicylic acid (FTS) were purchased from Santa Cruz 112 
Biotechnology. The structures of these various TRPA1 modulators are shown in Figure 1. 113 
The stock solutions of the compounds were made and serially diluted to lower half-log scale 114 
concentrations in dimethyl sulfoxide (DMSO, 100 %, analytical reagent grade, Fisher 115 
Scientific), and thus the concentration of DMSO was maintained constant in a given total 116 
volume of sample.  117 
 118 
2.1.2 Chemistry. 119 
The Orion Corporation-disclosed aryl sulfonamide derivative (S)-N-(4-chlorobenzyl)-1-((4-120 
fluorophenyl)sulfonyl)pyrrolidine-2-carboxamide (ASD) [36], the series of CADs and related 121 
derivatives were synthesized in-house using standard methods (see Supporting Information 122 
for details). Briefly, three synthetic routes were followed to synthesize the CADs. In one 123 
approach, the cinnamic acid derivative was converted to its corresponding acid chloride, 124 
which was coupled to methyl anthranilate, and the resulting methyl N-cinnamoylanthranilate 125 
was then hydrolyzed to yield the corresponding N-cinnamoylanthranilic acid derivative 126 
(Scheme 1). In the second approach, Meldrum's acid was reacted with anthranilic acid to 127 
produce 2-[(carboxyacetyl)amino]benzoic acid, which was then condensed with a 128 
benzaldehyde derivative via a piperidine-catalysed Knoevenagel condensation, producing N-129 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
8 
 
cinnamoylanthranilate as the piperidinium salt which was acidified to yield the final product 130 
(Scheme 2). In the third approach, a secondary amino acid was reacted with cinnamoyl 131 
chloride under basic conditions, and the resulting salt was acidified to yield the product 132 
(Scheme 3). Compound purity was assessed by satisfactory CHN combustion elemental 133 
microanalysis, 1H and 13C NMR spectroscopy, and a constant melting point. Chemical and 134 
spectroscopic data obtained for compounds synthesized (see Supporting Information) agreed 135 
closely with that reported, where available, in the literature. Stock solutions of these 136 
compounds were prepared as described above (Section 2.1.1). 137 
 138 
2.2 Cell culture. HEK293 cells stably transfected with either pcDNA3.1(+) constructs 139 
containing cDNA for hTRPA1 [37], hTRPM8 [38], hTRPA1 mutants or pcDNA3 (mock) 140 
were grown in Dulbecco's Modified Eagle's Medium (DMEM) containing 25 mM 4-(2-141 
hydroxyethyl)-1-piperazine ethanesulfonic acid (HEPES) and 4.5 g l-1 glucose, supplemented 142 
with 2 mM L-glutamine, 100 U ml-1 penicillin, 100 U ml-1 streptomycin (all from Lonza), 10 143 
% v/v heat inactivated Fetal Bovine Serum (Life Technologies) and 0.25 mg ml-1 geneticin 144 
(G418 Sulfate, Corning). The cells were grown in T75 tissue culture flask (Greiner Bio-One 145 
CELLSTAR) in a humidified cell culture incubator with 5 % CO2 at 37 °C. When the cells 146 
reached ~90 % confluence, they were harvested in phosphate buffered saline (PBS, Sigma-147 
Aldrich) solution and centrifuged at 205 × g for 4 min for calcium signaling experiments. 148 
 149 
2.3 Calcium signaling. The modulatory effects of the CADs were evaluated on hTRPA1, 150 
hTRPM8 and pcDNA3 (mock) transfected-HEK293 cells using a fluorescence-based calcium 151 
signaling assays at room temperature, either in the cuvette-based system or a micro-well plate 152 
system as described below. 153 
 154 
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Cuvette-based system: A previously reported protocol was followed [38]. Briefly, the cell 155 
pellet obtained from ~90 % confluence in T75 flask was resuspended in 0.5 ml complete 156 
DMEM and incubated with 2.5 µl of 2.5 µg µl-1 Fluo-3AM fluorescent dye (λEx/Em 506/526 157 
nm, Life Technologies) for 30 min at room temperature with gentle rotary mixing (50 rpm). 158 
The cells were washed with PBS by centrifuging as before, and the pellet was resuspended in 159 
isotonic assay buffer [38] (10 mM HEPES, 145 mM NaCl, 5 mM KCl, 1 mM MgCl2.6H2O, 1 160 
mM CaCl2 and 10 mM D-(+)-glucose made in double distilled water, and pH was adjusted 161 
with NaOH) at a density of 5 × 106 cells ml-1. The cell suspension (100 µl) was added to 162 
cuvettes containing the assay buffer (1.9 ml). The assays were carried out using a PTI 163 
fluorometer with FelixGX version 4.2.2 software. The amount of [Ca2+]i released upon 164 
activation of TRP channels were measured as a real-time-based fluorescence spectrum. The 165 
baseline of a spectrum was recorded for 20 s before the addition of a test compound (agonist) 166 
and the response was recorded for another 90 s, followed by the addition of calcimycin (2 167 
µM) and recording for further 30 s. In antagonist assays, the standard antagonist, the vehicle 168 
control or the test compounds were pre-incubated with cells for 10 min prior to the addition 169 
of a standard agonist, and the spectrum was recorded as before.  170 
 171 
Micro-well plate system: 96-Well cell culture microplates (black polystyrene, flat µClear 172 
bottom, Greiner Bio-One) were coated with poly-D-lysine (PDL, MW 70-150 kDa, Sigma-173 
Aldrich, 50 µg ml-1 prepared in sterile PBS) as follows: PDL was added to the wells (200 µl 174 
cm-2) and incubated for an hour at room temperature, excess PDL solution was aspirated and 175 
the wells were washed with PBS (2 × 100 µl per well), and air-dried at room temperature for 176 
2 h in a safety cabinet. Cell suspension (200 µl of 12500 cells per well in complete DMEM) 177 
was added to the wells and incubated in the cell culture incubator (95% air and 5% CO2 at 37 178 
°C) for 48 h to yield a final concentration of 5 × 104 cells per well. The culture medium was 179 
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replaced with 100 µl of 2 µM Fluo-4AM [λEx/Em 494/506 nm (Life Technologies), diluted in 180 
phenol red-free DMEM (Life Technologies) from DMSO stock] and incubated in the dark at 181 
room temperature for 45 min. The cells were rinsed with PBS (2 × 100 µl per well), and the 182 
isotonic assay buffer (100 µl per well for agonist assays or 50 µl per well for antagonist 183 
assays) was added to the wells. In antagonist assays, the cells in 50 µl buffer were incubated 184 
with 50 µl antagonists for 10 min before assaying. The assays were carried out using a 185 
FlexStation3 Molecular Devices with the SoftMax Pro Software version 5. The protocol 186 
utilized was adapted from the literature [39, 40]. Briefly, the real-time-based fluorescence 187 
spectra were recorded using the read-mode/type: Flex fluorescence (RFUs) bottom-read. An 188 
excitation and emission wavelengths of 485 and 538 nm were used for measurements with 189 
530 nm auto cut-off. Each spectrum was recorded for a total run time of 240 s, where the 190 
baseline was recorded for 20 s, and at the end of which the first addition (compound) was 191 
made followed by the second addition (calcimycin) at 180 s. 192 
 193 
To determine the reversibility of an antagonist, after pre-incubation, the cells were washed 194 
with the assay buffer and resuspended in fresh assay buffer, and the response for the TRPA1 195 
standard agonist CA (30 µM) was examined. Competitiveness of an antagonist was 196 
determined by pre-incubating cells with the test antagonist compound of a known 197 
concentration for 10 min and by considering the shift in the dose-response curve of CA with 198 
and without the inhibitor.  199 
 200 
2.4 Graphical and statistical analyses. The agonism and antagonism responses were 201 
calculated either as a percentage of calcimycin or a standard agonist respectively, using the 202 
differences in the maximum and minimum relative fluorescence unit (∆RFU) values. Initial 203 
screening results correspond to three independent experiments (N = 3), and the errors 204 
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reported are the standard error of the mean (SEM). The dose-response curves were plotted 205 
and analyzed using GraphPad Prism version 5.03, and the values of logEC50 and logIC50 were 206 
obtained with their SEM. Each data point on a dose-response curve corresponds to the mean 207 
of three independent experiments (N = 3), performed either in duplicates (n = 6) or triplicates 208 
(n = 9), with their SEM. The responses were normalized by subtracting the noise/response 209 
obtained for the vehicle control (DMSO). In antagonist assays, the maximum response was 210 
obtained by normalising the standard agonist response to 100 %. Thus, in antagonist assays, a 211 
higher percentage value indicates a lower inhibitory effect by the test compound. To 212 
determine statistical significance between groups, the one-way analysis of variance 213 
(ANOVA) at p < 0.05 was carried out.  214 
 215 
The standard agonists and antagonists for positive controls were chosen, based on the ion 216 
channel specificity and potency of the ligands, and a concentration near or above EC50 or IC50 217 
were used in the assays. The standard agonists used for the hTRPA1 channels were CA (30 218 
µM), ACR (30 µM) or AITC (10 µM), and for hTRPM8 was WS5 (1 µM). The standard 219 
antagonists used were the potent TRPA1 selective A967079 (100 or 300 nM) and TRPM8 220 
selective AMTB.HCl (1 or 3 µM).  221 
 222 
2.5 Indirect measure of inertness towards covalent modification. As CADs could 223 
conceivably react with the TRPA1 via a conjugate addition processes, we wanted first to 224 
disprove that they reacted with a model nucleophile in the absence of the channel (see similar 225 
studies in [41]). Thus compound 1a (4 equiv., 226 mM) and N-acetyl-L-cysteine methyl ester 226 
(1 equiv., 56 mM) or N-acetyl-L-cysteine (1 equiv., 61 mM) in d6-DMSO were mixed 227 
together, and the progress of any reaction was monitored using 1H NMR spectra recorded at 228 
25 °C and at known time intervals. 229 
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 230 
2.6 Site-directed mutagenesis. hTRPA1 mutants C621A (site of covalent modification) [13], 231 
F909A or F944A (sites of non-covalent interaction identified by [16, 17]) cDNAs were 232 
produced using a QuikChange Lightening Site-Directed Mutagenesis kit (Agilent 233 
Technologies) as instructed in their manual, using pcDNA3.1(+) as the template and hTRPA1 234 
primers containing the mutants (synthetic oligonucleotides purchased from Eurofins 235 
Genomics MWG Operon). Briefly, hTRPA1 mutants strands were synthesized by performing 236 
18 cycles of PCR, followed by digestion of the parental- and hemi-methylated supercoiled 237 
dsDNA in the amplified products with Dpn I restriction enzyme. The amplified DNA was 238 
then transformed into XL10-Gold ultracompetent cells (E. coli) treated with β-239 
mercaptoethanol. Plasmid DNA was isolated from the E. coli and purified using a 240 
NucleoSpin® Plasmid DNA purification miniprep kit (Macherey-Nagel) according to the 241 
manufacturer's protocol. The dsDNA samples were quantified (NanoDrop Lite 242 
Spectrophotometer, Thermo Scientific), and sequenced (Eurofins Genomics DNA sequencing 243 
service) and compared against the parent hTRPA1 sequence (sequence ID: Y10601) to 244 
confirm the mutations.  245 
 246 
HEK293 cells were transfected with the hTRPA1 mutants dsDNA (0.3 µg µl-1) separately 247 
using FuGENE® 6 Transfection Reagent (Promega) as per the manufacturer's instructions. 248 
The transfection reagent FuGENE and DNA were added in 3:1 ratio. G418 (0.5 mg ml-1) 249 
resistance cells were then expanded in T25 and T75 flasks sequentially. The transfected cells 250 
were single cell cloned by serial dilution in a 96-well cell culture plate following Corning's 251 
procedure. Monoclonal cells were transferred to a 6-well cell culture plate and then into T75 252 
flasks for expansion. The cells were characterized with known hTRPA1 specific agonists and 253 
antagonists using the calcium signaling technique and compared against the WT-hTRPA1 254 
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responses to determine the level of TRPA1 protein stably expressed in the transfected 255 
HEK293 cells. The known TRPA1 ligands characterized in the hTRPA1 mutants were CA, 256 
AITC, ACR, menthol, thymol, carvacrol, eugenol, FFA, MFA, DCF, NPPB, URB597, FTS, 257 
(˗)-nicotine, NDGA, probenecid, HC030031, AP18, A967079 and ASD. 258 
 259 
2.7 Electrophysiology. Experiments involving animals were performed by IR Pharma 260 
(London, UK). Experiments were performed in accordance with the U.K. Home Office 261 
Guidelines for Animal Welfare based on the Animals (Scientific Procedures) Act of 1986 and 262 
the ARRIVE guidelines [42]. Vagus nerves of eight male Dunkin-Hartley guinea pigs 263 
(300˗400 g) were isolated, characterized and experimented as described previously [43, 44]. 264 
Compound stock solutions were prepared in DMSO and diluted 1000× in Krebs-Henseleit 265 
(KH) buffer. The depolarization was recorded in mV. To determine if a compound caused 266 
activation of the nerve, non-cumulative concentration responses to potential tussive stimuli 267 
were carried out. A control response to the TRPV1 agonist capsaicin (1 µM) was carried out 268 
to determine nerve viability, following which the nerve was stimulated with single 269 
concentrations of a test compound for 2 min. After application of each concentration of the 270 
compound, the nerve was washed with KH buffer until it returned to baseline, and this was 271 
repeated with the full range of concentrations. A similar stimulation was also carried out with 272 
the vehicle control (DMSO). A further control response to TRPA1 agonist acrolein (300 µM) 273 
was carried out at the end of the experiment to determine nerve viability. 274 
 275 
In order to study antagonism, the nerve was exposed to the agonist ACR (300 µM) for 2 min 276 
and washed with KH buffer until the response returned to baseline. This was repeated to 277 
provide two control agonist responses. The nerve was then pre-treated with a test compound 278 
for 10 min, and then re-stimulated with ACR (300 µM) for 2 min 20 s (the additional 20 s 279 
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was to allow for the changeover of stimuli) to assess if the compound was able to affect the 280 
magnitude of the depolarization induced by the ACR. Following a brief washout, the nerve 281 
was exposed to ACR (300 µM) for 2 min to provide a recovery response to ensure nerve 282 
viability and that the compound was washed off. 283 
 284 
3. Results 285 
3.1 Calcium signaling. The CADs were evaluated in HEK293 cells stably transfected with 286 
hTRPA1, hTRPM8 or pcDNA3 using a fluorescence-based calcium signaling technique. 287 
Agonism of the compounds were measured by assessing the Ca2+ influx in TRPA1-HEK293 288 
cells upon exposure to the test compounds relative to calcimycin (calcium ionophore, 289 
A23187), and antagonism of the compounds were measured by the ability of the test 290 
compounds to antagonize the agonism of a standard agonist. Hence, the agonism and 291 
antagonism responses of the compounds are presented as the percentage of calcimycin and 292 
standard agonist, respectively (Tables 1 and 2). The vehicle control (0.2 or 0.4 % DMSO) had 293 
no significant activity in hTRPA1 and in mock transfected-HEK293 cells (data not shown), 294 
but had a slight antagonising effect (inhibits ~20 % of WS5 response) in hTRPM8. 295 
 296 
Carboxylic acid-containing compounds were evaluated as their corresponding carboxylate 297 
salt due to the isotonic assay buffer (pH 7.4). Even so, for some derivatives insolubility in the 298 
buffer at higher concentrations (300 µM, or in some cases >100 µM) prevented completion of 299 
the dose-response curve (Fig. 3). Most of the CAD esters were partially soluble or insoluble 300 
above 3 µM, and hence screening at higher concentrations was not possible. The CADs, 14 301 
and 15 autofluoresced in the wavelength region of Fluo-3 and Fluo-4 dyes, so screening was 302 
not possible. Due to broad absorption ranges for these two CADs other long-wavelength 303 
calcium dyes were found not to be suitable either.  304 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
15 
 
 305 
3.2 CAD Structure-Activity Relationship in hTRPA1. In the initial screening of N-306 
cinnamoylanthranilic acids (Table 1), the CADs 1-10, 20 and 21 showed ≥25 % agonism at 307 
30 µM and ≥50 % inhibition at 100 µM. The agonists 2, 3, 20 and 21 showed weak 308 
antagonism in the initial screen, relative to other antagonists (e.g. 4, 5 and 6), so full 309 
inhibition curves were not done and IC50 values were not calculated. The CADs 11, 12, and 310 
16-19 showed weak agonism (<25 %) whereas CAD 13 showed no agonism. However, the 311 
CADs 11-13 showed ≥40 % inhibition, and 16-19 showed weak inhibitory effect (<30 %). In 312 
the initial screening of methyl N-cinnamoylanthranilates (Table 2), all the evaluated esters, 313 
including 1a, 3a-8a, 13a-15a, and 20a-22a, were agonists (Table 2). Most of the methyl N-314 
cinnamoylanthranilate esters at 3 µM showed a similar level of agonism to that of their 315 
corresponding N-cinnamoylanthranilic acid derivatives at 30 µM. However, apart from 20a 316 
and 21a, none of the esters showed antagonism. Dose-response curves were carried out for N-317 
cinnamoylanthranilic acids that showed higher than 25 % agonism at 30 µM, and for those 318 
which had high antagonism and partial agonism. As can be seen from the curves, the effects 319 
observed were dose-dependent (Fig. 3).  320 
 321 
The halogenated CADs 4 and 5, with a bromo or chloro substituent at the para-position, 322 
had similar potency, whereas the fluorinated CAD 7 showed an increase in EC50 and IC50, 323 
relative to other halogens in the series. As the halogenated CADs 4-7 showed potent agonism 324 
and antagonism, it was thought that they might possess desensitising effects following 325 
activation of the channel. This was confirmed by recording the real-time spectra for 10 min 326 
(Fig. 4a,b). Since CA and FFA are known to have desensitising effects, [30, 45] they were 327 
also evaluated along with the CADs for comparison. At the concentration eliciting a 328 
maximum response, the elevated Ca2+ level caused by the agonism was sustained (Fig. 4b), 329 
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and at a submaximal concentration the effect dropped over 200-300 s. On continuous 330 
exposure to an agonist a diminished response was obtained (Fig. 4c-f), due to desensitization 331 
of the channel (see [30]). For the CADs tested at 10 µM the agonism response dropped back 332 
nearer to the spectral baseline within 10 min of administration and desensitized the agonism 333 
of the CA (30 µM) standard agonist (Fig. 4c-f). Due to this bimodal activity, potent agonism 334 
and desensitising effect, a washout experiment was carried out to examine the reversibility of 335 
the compounds. The desensitising effect shown by the halogenated CADs on hTRPA1 was 336 
found to be reversible up to 10 µM for 4 and 5, and up to 30 µM for 6 and 7, and were 337 
irreversible at higher concentrations (Fig. 5).  338 
 339 
The CADs with a methyl (8) or methoxy (10) group possessed similar agonist activity at 340 
30 µM in the initial screening. However, on comparing the EC50 of 8 and 10, CAD 8 341 
appeared to be less potent. Disubstituted CADs 11 and 12 with electron donating groups 342 
(EDGs) exhibited partial agonist and antagonist activities, whilst 13 showed only an 343 
antagonistic effect and no agonism below 100 µM. Nevertheless, the disubstituted CADs 11 344 
and 12 were less potent antagonists compared to the monosubstituted 13.  345 
 346 
Ortho-substituted CADs 6 and 9 were less efficacious, relative to their corresponding 347 
para-substituted analogues 5 and 10. In addition, α,β-saturated derivatives 16 and 17 showed 348 
poor activity at 30 µM compared to the corresponding CADs 1 and 10 with an α,β-349 
unsaturation. The compounds 18 and 19 with a non-planar ring replacing the anthranilate 350 
moiety showed weak responses relative to the parent compound 1. The α-substituted CADs 351 
either with a methyl or phenyl group were more potent agonists (20 and 21) relative to the 352 
unsubstituted CAD (1). Among the α-substituted CADs 20 and 21, and unsubstituted CAD 1, 353 
the derivative 21 showed pronounced agonist potency.  354 
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 355 
The N-cinnamoylanthranilic acid methyl esters evaluated in hTRPA1 at 3 µM (Table 2) 356 
showed a similar level of agonism to their corresponding N-cinnamoylanthranilate derivatives 357 
at 30 µM (Table 1), but there were no considerable antagonism shown by the esters, except 358 
for 20a and 21a with desensitising effects. 359 
 360 
3.3 Channel selectivity. To determine the channel selectivity of CADs, they were assessed in 361 
pcDNA3 mock-HEK293 cells for agonism, and in hTRPM8-HEK293 cells for both agonism 362 
and antagonism. The CADs, evaluated at 30 and 100 µM, and CAD methyl esters, at 3 µM, 363 
did not show any response in the negative control pcDNA3 mock-transfected HEK293 cells 364 
(N = 3, data not shown). 365 
 366 
There was no agonism seen for any CADs in hTRPM8-transfected HEK293 at the 367 
concentrations 30 and 100 µM of N-cinnamoylanthranilates, and 3 µM of methyl N-368 
cinnamoylanthranilates (data not shown), except for 21 and 21a which exhibited weak 369 
agonism (Tables 1 and 2). The majority of the compounds which were hTRPA1 agonists, 370 
were weak hTRPM8 antagonists at high concentrations. Dose-response curves were carried 371 
out for, 3, 4, 6, 9, 20 and 22a, that showed high antagonism (Tables 1 and 2), amongst which 372 
22a was the most potent hTRPM8 antagonist with IC50 10 µM (Fig. 3g). In addition, it was 373 
observed from the IC50 values that the CAD 4, which showed antagonism in both hTRPA1 374 
and hTRPM8, was more potent in hTRPA1. However, the CADs 6 and 9 had only a 10 µM 375 
difference in the IC50 values obtained against hTRPM8 and hTRPA1 (Table 1). 376 
 377 
3.4 Determination of possible binding sites through mutagenesis studies.  378 
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Binding site. CADs could undergo covalent modification due to the presence of an α,β-379 
unsaturated carbonyl group. Previously we have used NMR scale model reactions of reactive 380 
molecules with cysteine as a quick way of gauging susceptibility of a molecule towards 381 
covalent modification of a TRPA1 cysteine residue, and good correlation with agonism levels 382 
has been observed [41]. Therefore, the propensity of CADs to react through conjugate 383 
addition of the thiol group in cysteine (N-acetyl-L-cysteine methyl ester or N-acetyl-L-384 
cysteine) to the α,β-unsaturated double bond was evaluated for the representative CAD 1a 385 
(Scheme S4, Supporting information) using a proton NMR time study. This CAD showed no 386 
reactivity to the thiol group of cysteine in d6-DMSO, as monitored by changes in intensity or 387 
appearance of new peaks in the NMR spectrum over 6 h (data not shown). However, to rule 388 
out covalent modification of the channel completely, studies of CADs with C621A mutants 389 
were conducted as part of a study to determine the binding site of the CADs. 390 
CADs and a range of other known hTRPA1 active ligands were characterized in HEK293 391 
cells stably transfected with hTRPA1 mutants C621A, F909A or F944A at concentrations 392 
corresponding to the maximum response or closer to the EC50 or IC50 obtained in wild-type 393 
(WT)-hTRPA1 HEK293 cells. The EC50 and IC50 values obtained in the WT-hTRPA1 (Table 394 
3) were broadly consistent with the values found in the original reports, given possible 395 
variations in the assay methods, conditions, species and/or cell lines. Significantly reduced 396 
agonism was obtained, as expected, for the electrophilic compounds, CA, AITC and ACR in 397 
the mutant C621A-hTRPA1. Reduced agonism was also observed for the non-reactive 398 
compounds menthol, carvacrol, FFA, DCF, NPPB, FTS, probenecid and 22a, relative to the 399 
responses obtained in WT-hTRPA1-HEK293 (Fig. 6a-e). With the exception of the saturated 400 
analogue 22a, CADs produced increased responses relative to that observed in the WT-401 
hTRPA1 (Fig. 6e).  402 
 403 
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A967079, AP18, CAD 13 and ASD all had reduced antagonistic responses in F909A-404 
hTRPA1 expressing HEK293 cells relative to WT-TRPA1 expressing cells (Fig. 6f). No 405 
reduction in antagonism was observed for HC030031 in the F909 mutant. Menthol and 406 
carvacrol also showed a reduced agonist effect in the absence of F909, however most of the 407 
other compounds showed a significantly increased agonist response in this mutant compared 408 
to the WT (Fig. 6a-e). 409 
 410 
In the mutant F944A-hTRPA1 HEK293 cells a significant drop in activity was found for 411 
ACR, menthol, carvacrol, eugenol and FFA, NDGA, probenecid, CADs 3 and 22a, 8 and 20, 412 
ACA, A967079 and AP18 and ASD, relative to the responses in WT-hTRPA1 (Fig. 6). In the 413 
case of ACA and 3, reduced responses were obtained only at a lower concentration (10 µM) 414 
and not at a higher concentration (30 µM), as shown in Fig. 6e.  415 
 416 
3.5 Electrophysiology. The agonist and antagonist effects of the compounds, 3 and 5 at 100 417 
µM, and 13 at 300 µM, were tested on fully characterized isolated guinea pig vagus nerve 418 
preparations. The compounds showed a small degree of activation of the vagus nerve (Fig. 419 
7a-c), with 3 having the largest effect as in the hTRPA1-HEK293 cells. However, the 420 
potency of the responses obtained in tissue (nerve) did not compare to those obtained in 421 
HEK293 cells overexpressing hTRPA1.  422 
 423 
4. Discussion 424 
TRPA1 is activated by a wide range of stimuli. Some of the chemical modulators activate the 425 
channel via covalent modification of specific residues on the N-terminal of the channel [6, 11, 426 
12], however a large number do not possess the reactive groups to do likewise [12]. Here we 427 
have studied CADs as modulators of TRPA1 activity, and investigated where these 428 
compounds bind to the channel. Comparing trends in the SAR of the acid CADs against 429 
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hTRPA1, we noted the parent (unsubstituted) compound 1 had a moderate agonistic effect, 430 
and the electron withdrawing group (EWG)-substituted CADs 2 and 3 were more potent 431 
agonists. The halogenated CADs (4 - 7), with inductive electron withdrawing but lone pair 432 
donating properties showed potent agonism with desensitising effect, and the CADs 8 - 10, 433 
with a weak/moderate electron donating group (EDG), showed bimodal activity, that is they 434 
possessed partial agonism and antagonism. As the electron donating nature of the EDG 435 
becomes stronger the agonism of the compounds decreased and became antagonists (11 - 13). 436 
The potent agonism and antagonism of the halogenated CADs was due to a desensitising 437 
effect following activation of the channel, as was also shown for FFA [30]. This was 438 
reversible at low CAD concentration (<10µM) but irreversible at higher concentrations. 439 
α,β-Saturated analogue 16 and 17 showed poor activity compared to the 440 
corresponding α,β-unsaturated CADs. However it is interesting to note that the related, 441 
flexible derivative NPPB, a classic chloride ion channel antagonist, is a sub-micromolar 442 
agonist of TRPA1 [35]. Unlike the CADs studied, NPPB possesses a nitro group in the 443 
anthranilate ring, and replacing the anthranilate moiety in our CADs with a saturated cyclic 444 
amino acid (18 and 19) produced weak responses. This suggests that the anthranilate moiety 445 
probably plays a key role in the activity of the CADs. 446 
The agonism of structurally related compounds in the literature including ACA, an 447 
inhibitor of several TRP channels, [32], and SB366791, a selective TRPV1 antagonist [33, 448 
34], were evaluated against hTRPA1-HEK293. ACA [32], with a 4-pentyl substituent, 449 
activated hTRPA1 potently relative to the 4-methyl substituted CAD 8. Despite being similar 450 
to CAD 5 (but lacking COOH on the N-aryl ring), SB366791 had no agonism in hTRPA1 451 
(data not shown). A similar trend to that observed for the EWG and EDG substituted CADs, 452 
has also been reported for modulation of hTRPA1 by substituted benzylidenemalononitriles. 453 
[46] 454 
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 455 
HEK293 cells endogenously express a number of ion channels and receptors, including 456 
purinoceptors (P2Y1 and P2Y2) [47], voltage-gated potassium channels [48, 49], sodium 457 
channels (β1A and Nav1.7) [50, 51], sphingosine-1-phosphate receptors (Edg-1, Edg-3 and 458 
Edg-5) [52], calcium channels [53] including TRPC1, TRPC3, TRPC4, TRPC6 and TRPC7 459 
[54, 55], and M3 muscarinic acetylcholine receptor [56]. The CADs and methyl N-460 
cinnamoylanthranilate, did not activate the negative control mock-transfected HEK293 cells, 461 
proving that in TRPA1-HEK293 cells the compounds were selective to TRPA1. 462 
 463 
TRPM8, a cold-sensitive channel [57], is stimulated by a number of TRPA1 modulators 464 
[58, 59]. Therefore, CADs were evaluated against stably transfected hTRPM8-HEK293 cells 465 
for selectivity between these two channels. CADs active in hTRPM8 contained either a 466 
halogen, an ortho- or an α-substituent. Interestingly, most of the TRPA1 agonists were 467 
hTRPM8 antagonists at higher concentrations. However assays against a range of other ion 468 
channels are necessary to confirm overall channel selectivity. 469 
 470 
Looking at the physicochemical properties (Table S1) among similar analogues, 471 
compounds possessing a higher clogP were the more potent agonists, as also seen in 472 
examples in the literature [35, 60]. Generally, the CADs with a higher number of hydrogen 473 
bond donors and acceptors, larger topological polar surface area and logS, and lower logP 474 
had greater inhibitory effects with poor or no hTRPA1 agonism (Table S1). 475 
 476 
To determine the binding site(s) of the ligands, mutant TRPA1-expressing HEK293 cell 477 
lines were created. The residues mutated were chosen based on the functional groups on the 478 
ligands and the residues that could participate in either covalent modification (C621 [13]) or 479 
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through non-covalent aromatic interactions (F909 [16] and F944 [17]). C621A-hTRPA1 480 
showed significantly reduced agonism responses for electrophilic compounds, in line with 481 
previous reports [11, 12]. We also observed significantly diminished agonism with non-482 
reactive compounds. A similar type of effect had been previously described for menthol, 483 
NPPB and FTS [35]. However the reduced effects observed with NPPB and FTS in the 484 
mutant C621A were not statistically significant, though a significant reduction in agonism 485 
was observed with the mutations of different cysteine residues at the N-terminus [35, 61]. The 486 
TRPA1 antagonists could not be evaluated in this mutant, since the hTRPA1 standard 487 
agonists CA, AITC and ACR bind to the mutated site. In addition to the 1H NMR study 488 
carried out with CAD 1a, the findings with the C621A mutant further suggest that CADs do 489 
not undergo covalent modification at the TRPA1 N-terminal cysteine. The reduced agonism 490 
observed for CAD 22a is however an anomaly, but this can be explained by chemical 491 
reactivity observed for this ester. When attempting to hydrolyse 22a, to get the free acid, the 492 
compound eliminated the phenoxy group, presumably via an E1cb mechanism, to yield an 493 
acrylamide derivative. With reduced conjugation and no β-substituent, this compound would 494 
be expected to be much more likely to undergo covalent addition reaction compared to a 495 
cinnamide. Thus, the change in modulation of 22a in the C621A mutant could be explained if 496 
such a process also takes place inside the cell. 497 
 498 
For F909A-hTRPA1, significantly reduced inhibition was observed as expected for 499 
A967079 relative to the WT-hTRPA1 response [16]. Significantly reduced antagonism was 500 
also observed for the structurally similar oxime AP18. Since the tested antagonists with 501 
distinct structures, including CAD 13 and ASD, also showed significant differences in this 502 
mutant, F909 residue appears to be a key residue for antagonist binding in hTRPA1. Both 503 
CAD 13, ASD and HC030031 incorporate two aromatic rings joined by a linking group. The 504 
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reduced antagonism was not observed for HC030031, but this could be explained by the fact 505 
that the aromatic methyl xanthine half of the molecule is a larger bicyclic heteroaromatic ring 506 
structure, as opposed to a single benzenoid rings in CAD 13 and ASD; it is therefore likely to 507 
have a different binding site. There was also a drop in the agonism of menthol and carvacrol 508 
in the absence of the F909. As menthol lacks aromaticity and cannot participate in aromatic π 509 
interactions, it appears a more general hydrophobic interaction may be involved here, 510 
possibly also involving residues neighbouring F909, such as T874. For most of the other 511 
compounds the responses were significantly higher than that observed in WT-hTRPA1. This 512 
could be due to changes in the structural conformation of hTRPA1 as a result of the 513 
substitution of the aromatic residue F909 to alanine. 514 
 515 
The mutant F944A-hTRPA1-HEK293 cells displayed a significantly reduced response to 516 
many of the ligands evaluated, including the non-aromatic compounds ACR and menthol that 517 
cannot participate in π-π interactions. The cryo-EM structure of TRPA1 shows that F944 is 518 
buried within the channel structure [16], and apparently closed to binding without 519 
reorganization of the channel structure. Samanta et al [62] used limited proteolysis and mass 520 
spectrometry to evaluate the effect of a small number of non-electrophilic channel modulators 521 
(menthol, antagonist A967079, and agonist PF-4840154) on mouse TRPA1. In that work, 522 
several regions of TRPA1 were proposed as experiencing conformational change upon 523 
binding of the ligands studied. However, F944 and the S5 and S6 helices were not amongst 524 
those implicated. Nevertheless our results, using a wider range of modulators and with 525 
hTRPA1, indicate that it is possible that the reduced activities observed for our F944A 526 
mutant is also indicative of significant structural reorganizations of the S5 and S6 helices 527 
upon ligand binding. The responses obtained for A967079 in both F909 and F944 mutants 528 
were equal. However, the analogue AP18 had significant differences in response despite the 529 
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close similarity in their structures; the AP18 inhibition was nearly abolished in the mutant 530 
F944A, but not in F909A. ASD, however, preferentially binds F909 over F944, possibly due 531 
to its greater size, site accessibility and location of the amino acid in the channel structure. 532 
The residues F909 and F944 from each TRPA1 subunit are located in a ‘ring’ amongst the 533 
S5 and S6 helices, a portion of the channel which is thought to be membrane bound [16] (Fig. 534 
8a-c). F909 is located at the bottom of a shallow pocket, whereas F944 is buried within the 535 
tertiary structure of the channel (Fig. 8c-d). Whilst previously EM studies have suggested the 536 
location of the A967079 binding site [16], this area is buried behind the F909 residue in the 537 
atomic model 3J9P. The drop-in activities of modulators in F909A and F944A demonstrated 538 
that the corresponding compounds may possibly bind to the aromatic phenylalanine in the 539 
hTRPA1 putative pore region non-covalently via π-π stacking and/or hydrophobic 540 
interactions. Whilst further structural biology will be needed to elucidate detailed ligand 541 
binding, derivatives with hydroxy groups, anthranilic acid derivatives such as non-steroidal 542 
anti-inflammatory drugs, CADs and aryl sulfonamide derivatives, showed significant 543 
reductions in responses in the mutant F944A, suggesting this residue might serve as a general 544 
determinant in the modulation of hTRPA1. Complete elimination of the responses were not 545 
observed with most of the ligands suggesting they may also interact with other nearby 546 
residues.  547 
 548 
The most potent CADs (3, 5 and 13) were also characterized on isolated guinea pig vagus 549 
nerves. Unfortunately, the potency seen in the TRPA1-HEK293 cells was not observed in the 550 
nerve tissue. ACR was used as the TRPA1 standard agonist to determine the inhibitory 551 
effects of the compounds in guinea pig vagus nerve tissue, as desensitization of responses 552 
were observed with the use of CA in depolarization measurements [45, 63]. As a positive 553 
control, incubation with the TRPA1 standard antagonist HC030031 inhibited the 554 
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depolarization induced by ACR. However, contrary to the antagonistic effects observed in 555 
hTRPA1-HEK293 cells, neither of the compounds 5 and 13 exhibited any antagonism against 556 
depolarization of the guinea pig vagus nerve by ACR. This discrepancy in results could be 557 
due to, but not limited to, experimental differences or a consequence of species difference. 558 
There is only 79% identity between the amino acid sequences of hTRPA1 and guinea pig 559 
TRPA1. The low sequence homology with 21% variation could cause differences in 560 
responses. Caffeine, menthol and thioaminals (e.g. 4-methyl-N-[2,2,2-trichloro-1-(4-nitro-561 
phenylsulfanyl)-ethyl]-benzamide), are potent antagonists in hTRPA1 but showed reduced 562 
potency, agonism or inactivity in rodent TRPA1 [64-66]. Similarly, rodent TRPA1 is 563 
activated by cold, whereas human and rhesus monkey TRPA1 are not [67]. The menthol and 564 
cold species difference were attributed to a single residue, V875 in primates and G878 in 565 
rodents [67]. 566 
 567 
A possible correlation is also noted between the various observed biological activities of 568 
CADs and TRP channels. This is plausible due to the known participation of TRP channels in 569 
a wide range of cellular functions [68]. Key to this suggestion is a study [69] which reports 570 
that TRPA1 is necessary for TGF-β signaling. Loss of the receptor significantly suppresses 571 
the mRNA expression of the inflammatory cytokines, IL-6, α-smooth muscle actin involved 572 
in fibrosis, substance P involved in inflammation, VEGF, collagen Iα1 and the 573 
phosphorylation of kinases induced by TGF-β, and thereby results in attenuation of 574 
fibrogenic and inflammatory reactions. Likewise, in the literature, the anti-allergic, anti-575 
inflammatory [18, 19], anti-oxidant [20], anti-fibrotic [70], anti-proliferative [22] and anti-576 
cancer [23] properties of CADs were related to inhibition of cytokines, chemokines and 577 
growth factors. Therefore the fundamental reason behind attenuation of cytokines and growth 578 
factors by CADs, might be the consequence of effects imposed by CADs on TRP channels. 579 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
26 
 
 580 
5. Conclusions 581 
The series of CADs possess various activities in hTRPA1, ranging from agonism, partial 582 
agonism, antagonism and desensitizing effects. The structurally related compound, ACA, an 583 
inhibitor of TRPM2, TRPM8, TRPC3, TRPC6 and TRPV1 [32] activates hTRPA1 with 584 
similar potency to those of other CADs evaluated in the study. CAD 13 (p-OH), with a strong 585 
EDG-substituent, and CAD 21 (α-Ph), show promise as a selective hTRPA1 antagonist and 586 
agonist, respectively. Using the key SARs found in the study, the structures of the 587 
compounds could be optimized to make CADs more potent modulators of TRPA1. Moreover, 588 
F944 was found to be a key residue for many TRPA1 active modulators, including menthol, 589 
anthranilates including fenamates and CADs, and ASD. Activity for these modulators was 590 
much reduced in the F944A mutant, indicating that this and other residues (F909) within the 591 
TRPA1 S5-S6 putative pore region are crucial for chemosensation.  592 
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Figure and Scheme Legends 
Scheme 1. Synthesis of N-cinnamoylanthranilate derivatives from cinnamic acids. The derivatives 1-8, 
13-17, 20, 21, and their corresponding methyl N-cinnamoylanthranilate ester derivatives, including 
22a, were synthesized using this approach. 
 
Scheme 2. Synthesis of N-cinnamoylanthranilic acid derivatives from aldehydes. The derivatives 9-12 
were synthesized using this approach. 
 
Scheme 3. Synthesis of N-cinnamoyl amino acids (rac-18 and S-19). 
 
Figure 1. Chemical structures of non-CAD TRPA1 modulators involved in this work. 
 
Figure 2. Chemical structures of the N-cinnamoylanthranilate and related derivatives synthesized and 
evaluated in this study. 
 
Figure 3. Dose-response curves of N-cinnamoylanthranilate derivatives in hTRPA1 (a - f) and 
hTRPM8 (g) HEK293 cells. Each data point on the curve represents the mean of three independent 
experiments (N = 3) in duplicates (n = 6) with their SEM. 
 
Figure 4. Real-time spectrum recorded for 10 min (incubation period) for the compounds with bimodal 
activity (potent agonism and desensitization) in hTRPA1-HEK293 cells. (a) cinnamaldehyde (CA, 30 
µM), (b) flufenamic acid (FFA, 100 µM), (c) p-Br CAD-4 (10 µM), (d) p-Cl CAD-5 (10 µM), (e) o-Cl 
CAD-6 (10 µM) and (f) p-F CAD-7 (10 µM). The concentration of CA in the second addition was 30 
µM. 
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Figure 5. (a) Desensitizing effect and (b) reversibility of halogenated N-cinnamoylanthranilic acids 4-7 
on hTRPA1-HEK293 cells. Each bar represents the mean ± SEM (N = 3, n = 6), and the statistical 
significance was determined using one-way ANOVA at *p < 0.05. 
 
Figure 6. Screening results of TRPA1 ligands in the hTRPA1 mutants, F909A, F944A and C621A, and 
comparison of the responses against WT-hTRPA1 HEK293 cells, (a-e) agonism and (f) antagonism. 
Each bar represents the mean ± SEM of N = 3 (n = 6), and statistical significance was compared 
relative to WT at *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001, using one-way ANOVA; 
black stars indicate significant reduction and grey stars indicate significant increase in response relative 
to WT. 
 
Figure 7. Effects of CADs 3, 5 and 13 on isolated guinea pig vagus nerve preparations, (a - c) agonism 
and (d) antagonism against acrolein (ACR, 300 µM) induced depolarization; each bar represents the 
mean ± SEM (N = 4). (e) Antagonism of CADs 5 and 13 against acrolein (300 µM in human TRPA1-
HEK293 cells; each bar represents the mean ± SEM (N = 3, n = 9).  
 
Figure 8. A. Human TRPA1 atomic model 3J9P showing the location of residues F909 (red) and F944 
(blue) as coloured spheres. These are located in the membrane portion of the channel. B. Top down 
view of the channel showing the central pore and the ‘ring’ of F909 and F944 residues. C. Close up of 
TRPA1 showing the F944 and F909 repeating residues. D. Close up with surface highlighting residues 
in red F909 (top) and T874 (bottom), and the location of the shallow pocket for putative antagonist 
binding. The location of F944 (blue) is buried and unavailable for ligand binding without significant 
structural movement. 
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Table 1. Screening results of the synthesized N-cinnamoylanthranilic acids in hTRPA1 and hTRPM8-transfected HEK293 cells. The 
concentrations at which the compounds were tested are specified in the corresponding column title. Dose-response curves in hTRPA1 were 
carried out for the compounds that showed >25 % agonist activity at 30 µM, and that had partial agonism and high antagonism, in the initial 
screening. Dose-response curves in hTRPM8 were carried out for the compounds which showed >60 % inhibitory effect in the initial 
screening. For compounds where an EC50 or IC50 could not be calculated, a dash (-) is given instead of a value. Each value represents the 
mean ± SEM (N = 3). 
Compound CAD variant hTRPA1-HEK293 hTRPM8-HEK293 
 
Agonism /  
(% calcimycin) 
30 µM 
N = 3 ± SEM 
Antagonism, 
CA response 
/ (% CA)  
100 µM 
N = 3 ± SEM 
LogEC50 / (M) 
n = 6,  
N = 3 ± SEM  
EC50 
/(µM) 
 
LogIC50 / (M) 
n = 6,  
N = 3 ± SEM 
IC50 
/(µM) 
Agonism / 
(% calcimycin) 
30 and 100 µM 
N = 3 ± SEM 
Antagonism, 
WS5 response 
/ (% WS5) 
100 µM 
N = 3 ± SEM 
LogIC50 / (M) 
n = 6,  
N = 3 ± SEM 
IC50 
/(µM) 
1 - 24 ± 1 42 ± 3 - - - - 
 
 
No agonism 
response was 
obtained for any 
of these 
compounds. 
48 ± 6 - - 
2 4-NO2 25 ± 1 33 ± 6 -3.7 ± 0.2 219 - - 39 ± 7 - - 
3 4-CF3 51 ± 1 28 ± 2 -4.57 ± 0.06 27 - - 17 ± 3 -4.5 ± 0.2 34 
4 4-Br 60 ± 3 6 ± 2 -4.94 ± 0.09 12 -5.0 ± 0.2 9 35 ± 2 -4.2 ± 0.4 59 
5 4-Cl 62 ± 1 7 ± 1 -5.00 ± 0.07 10 -5.4 ± 0.1 4 40 ± 5 - - 
6 2-Cl 44 ± 2 5 ± 2 -4.37 ± 0.07 42 -5.0 ± 0.1  11 25 ± 4 -4.7 ± 0.5 21 
7 4-F 37 ± 1 13 ± 4 -4.5 ± 0.1 30 -4.6 ± 0.1 26 61 ± 8 - - 
8 4-CH3 30 ± 1 40 ± 1 -3.8 ± 0.1 149 - - 48 ± 3 - - 
9 2-OCH3 33 ± 1 14 ± 2 -4.1 ± 0.1 75 -4.3 ± 0.2 51 32 ± 8 -4.4 ± 0.3 41 
10 4-OCH3 27 ± 1 19 ± 6 -4.3 ± 0.2 49 -4.9 ± 0.1 12 68 ± 8 - - 
11 3,4-(OCH3)2 6 ± 3 56 ± 13 - - -3.9 ± 0.2 126 65 ± 6 - - 
12 3-OEt-4-OH 5 ± 1 34 ± 6 - - -4.0 ± 0.3 106 73 ± 6 - - 
13 4-OH 1 ± 1 35 ± 11 - - -4.4 ± 0.1 43 70 ± 5 - - 
14 3,4-(OH)2 Fluorescing compounds  Fluorescing compounds 
15 4-N(CH3)2 
16 α,β-saturated 10 ± 3 81 ± 11 - - - - 48 ± 4 - - 
17 α,β-saturated, 4-OCH3 6 ± 1 74 ± 14 - - - - 57 ± 5 - - 
18 Pipecolinic acid 7 ± 1 71 ± 9 - - - - 72 ± 6 - - 
19 Proline 5 ± 2 79 ± 4 - - - - 65 ± 5 - - 
20 α-CH3 33 ± 2 29 ± 2 -3.9 ± 0.1 133 - - 28 ± 7 -4.6 ± 0.2 27 
21 α-Ph 66 ± 2 22 ± 1 -4.95 ± 0.04 11 - - 14 ± 1, 34 ± 3 not measured - - 
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Table 2. Screening results of the methyl N-cinnamoylanthranilates (3 µM) in hTRPA1 and hTRPM8-
HEK293 cells. As 2a (4-NO2) was insoluble in DMSO at room temperature, it was not evaluated. Each 
value represents the mean ± SEM (N = 3). 
Compound CAD variant hTRPA1-HEK293 hTRPM8-HEK293 
 
Agonism / 
/ (% calcimycin) 
3 µM 
N = 3 ± SEM 
Antagonism, 
CA response 
/ (% CA) 
3 µM 
N = 3 ± SEM 
Agonism /  
(% calcimycin) 
3 µM 
N = 3 ± SEM 
Antagonism, 
WS5 response /  
(% WS5) 
3 µM 
N = 3 ± SEM 
1a - 22 ± 1 
No inhibitory effect. 
 
 
 
No agonism. 
61 ± 1 
3a 4-CF3 29 ± 2 81 ± 11 
4a 4-Br 41 ± 2 79 ± 4 
5a 4-Cl 45 ± 2 70 ± 4 
6a 2-Cl 29 ± 2 53 ± 1 
7a 4-F 34 ± 3 85 ± 9 
8a 4-CH3 28 ± 3 88 ± 3 
13a 4-OAc 10 ± 1 84 ± 2 
14a 3,4-(OAc)2 12 ± 1 102 ± 2 
15a 4-N(CH3)2 27 ± 1 86 ± 22 
20a α-CH3 49 ± 2 73 ± 7 30 ± 4 
21a α-Ph 63 ± 2 51 ± 2  23 ± 4 48 ± 7 
22a Phenoxy  45 ± 2 (at 30 µM) No inhibitory effect. No agonism 12 ± 2 (at 30 µM) 
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Table 3. The EC50 and IC50 values of the known ligands obtained in hTRPA1-HEK293 cells using a 
FlexStation, compared with the literature values of the original findings. Abbreviations: FLIPR, 
fluorometric imaging plate reader assay; EP, electrophysiology; FS, FlexStation; ND, not determined; 
NE, not estimable. 
 
 Obtained value Literature value 
Ligand LogEC50 (M)  
± SEM 
EC50 EC50, species, assay [ref.] 
CA -5.07 ± 0.09 9 µM 61 ± 9 µM, mouse TRPA1-CHO cells, FLIPR.[29] 
ACR -4.57 ± 0.07 27 µM 5 ± 1 µM, human TRPA1-Xenopus oocytes, EP.[7] 
AITC -5.36 ± 0.04 4 µM 22 ± 3 µM, mouse TRPA1-CHO cells, FLIPR.[29] 
Menthol -4.5 ± 0.1 30 µM 95 ± 15 µM, mouse TRPA1-CHO cells, EP.[58] 
Thymol -4.22 ± 0.06 60 µM 20 µM, human TRPA1-HEK293 cells, FLIPR.[60] 
Carvacrol -4.78 ± 0.09 17 µM ND 
Eugenol -3.77 ± 0.09 168 µM 261 ± 9 µM, human TRPA1-HEK293 cells, EP.[71] 
FFA -5.16 ± 0.06 7 µM 24 ± 3 µM, WI-38 cells (human fibroblast), FS.[30] 
57 ± 5 µM, human TRPA1-HEK293 cells, FS.[30] 
MFA -4.78 ± 0.09 16 µM 61 ± 5 µM, WI-38 cells (human fibroblast), FS.[30] 
DCF -4.2 ± 0.1 56 µM 210 ± 22 µM, WI-38 cells (human fibroblast), FS.[30] 
NPPB -6.22 ± 0.09 0.6 µM 0.32 µM, human TRPA1-HEK293 cells, FLIPR.[35] 
ACA -4.55 ± 0.06 28 µM ND 
SB366791 inactive - ND 
NDGA -4.45 ± 0.08 35 µM 4.9 ± 1.7 µM, human TRPA1-HEK293 cells, FS.[72] 
FTS -6.08 ± 0.07 0.8 µM 7 ± 4 µM, human TRPA1-HEK293 cells, FLIPR.[73] 
URB597 -0.87 0.1 µM 24.5 ± 3.2 µM, human TRPA1-HEK293F cells, FLIPR.[74] 
Nicotine 0.34 2 M ~10 µM, mouse TRPA1-CHO cells, EP.[75] 
Probenecid NE - 4.2 mM, human TRPA1-CHO cells, FS.[39]  
Ligand LogIC50 ± SEM IC50 IC50, species, assay 
A967079 -7.10 ± 0.09 79 nM 67 nM against AITC (30 µM), human TRPA1- HEK293F cells, 
FLIPR[76] 
AP18 -5.35 ± 0.08 4 µM 3.1 µM against CA (50 µM), human TRPA1-CHO cells, FLIPR.[77] 
HC030031 -4.75 ± 0.09 18 µM 6.2 ± 0.2 µM against AITC (5 µM), human TRPA1-HEK293 cells, 
fluorescence-based plate reader.[78] 
ASD -5.0 ± 0.1 10 µM 12.5 µM against AITC (5 µM), human TRPA1-HEK293 cells, FS.[79, 
80] 
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Figure 1. 
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Figure 4 
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Figure 6 
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Figure 7 
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Figure 8 
 
 
 
